Welcome to the 2022 Lipid Nanoparticles Development Europe Summit
The LNP Development Summit has optimised your LNP development through end-to-end advanced particle characterisation, CQAs & process control for seamless scale-Up & GMP compliance.
Building on the success of the inaugural US meeting, the LNP Development Summit Europe gathered 80+ senior leaders dedicated to advancing LNPs across Formulation, Particle Engineering and Process Development disciplines to share their strategies and lessons learned.
In collaboration with Insmed, AstraZeneca, CSL Behring and Janssen, this 3-day summit solely focused on
Evaluating the LNP landscape, and what the current and potential uses are for LNPs in the future from varied payloads to disease applications with CSL Behring, AstraZeneca, University of Manchester, and Rothwell Figg IP Professionals
Improving particle characterisation, bio- and physiochemical properties of your LNP to enhance stability and product quality with Janssen
Devising the appropriate critical quality attributes and a QbD approach with analytical process techniques with AstraZeneca and QUB
Evaluating the latest technologies to achieve seamless scale-up and tech transfer while ensuring product quality Insmed, Sanofi and CPI
Outline on and off-target effects with immunogenicity and LNPs, from finding alternatives to PEG to the implication of unwanted immune response in future applications with Sanofi, and Voyager Therapeutics
Discussing regulatory, and CMC requirements for LNP GMP compliance with AstraZeneca and University of Joseph Fourier
Why attend?
Network with a group of hand-selected, senior industry leaders in the LNP development space
Benchmark against your peers to assess lessons learned and case studies
Assess potential partners that can help you with your characterisation, formulation and process development methods
2022 Speakers:
"Lipid Nanoparticles and mRNA therapeutics have entered an exciting stage of development and public awareness. Bringing together key experts from various stages of discovery, scale-up and manufacturing is important to help spread knowledge and aid further development and utilisation of this versatile drug modality." Senior Research Scientist, AstraZeneca
"Bringing industry experts to think about next generation therapies – use the learnings from COVID vaccine and hepatic delivery to drive other arenas of research within genetic medicine." Associate Director, Eli Lilly
"Networking with peers and gathering expertise, views and approaches in tackling the problems related to non-viral gene therapy." Head of Nanoparticle Research, CSL Behring
"The LNP Summit is offering excellent sessions and opportunities for network. I’m looking forward attending all the sessions, since are hot topics and previous times all talks were amazing; I am sure that will be the same also this time." Professor of Biofabrication & Advances Manufacturing, Queens University Belfast
"The meeting offers an excellent opportunity to find about scientific and technical developments in the field, and to connect with the industrial ecosystem in this exciting and fast moving field." Head of Center of Excellence – LNP, CPI
"It is valuable to learn about the latest science and network with key players in the area." Senior Lecturer in Pharmaceutics, Kings College London
Who was in the Room?
(From the LNP Formulation & Process Development US Summit)
Company Types:
Seniority:
